HBM HOLDINGS-B (02142) Signs Evaluation and Licensing Agreement with UMOJA BIOPHARMA

HBM HOLDINGS-B (02142) announced that its wholly-owned subsidiary Nona Biotech (Suzhou) Co., Ltd. (Nona Biotech) has entered into an evaluation and licensing agreement with Umoja Biopharma, Inc. (Umoja Biopharma) to combine Nona Biotech's HCAb Harbour Mice platform and NonaCarFxTM platform with Umoja Biopharma's VivoVecTM platform to jointly advance the development of several in vivo CAR-T cell products. The agreement symbolizes a further deepening and expansion of the strategic partnership established between the two companies in September 2024. Under the terms of the agreement, Nona Biotech will have the right to receive upfront payments, potential option payments, as well as collaboration project discovery and development-related milestone payments. Umoja Biopharma will be responsible for all subsequent development and commercialization work for the products. Umoja Biopharma, Inc. is a clinical-stage biotechnology company dedicated to developing more accessible and effective in vivo CAR-T cell therapies in the fields of oncology and autoimmune diseases. Umoja Biopharma's VivoVecTM in vivo gene delivery technology enhances the patient's own immune system's ability to combat disease. Supporting its core technology is the company's advanced lentiviral vector development and manufacturing facility located in Louisville, Colorado. Umoja Biopharma believes that its scientific research can improve the accessibility and effectiveness of immunotherapy, helping more patients to enjoy a better and more fulfilling life.